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The application of artificial intelligence (AI) may revolutionize the healthcare system, leading
to enhance efficiency by automatizing routine tasks and decreasing health-related costs,
broadening access to healthcare delivery, targeting more precisely patient needs, and
assisting clinicians in their decision-making. For these benefits to materialize, governments
and health authorities must regulate AI, and conduct appropriate health technology
assessment (HTA). Many authors have highlighted that AI health technologies (AIHT)
challenge traditional evaluation and regulatory processes. To inform and support HTA
organizations and regulators in adapting their processes to AIHTs, we conducted a
systematic review of the literature on the challenges posed by AIHTs in HTA and
health regulation. Our research question was: What makes artificial intelligence
exceptional in HTA? The current body of literature appears to portray AIHTs as being
exceptional to HTA. This exceptionalism is expressed along 5 dimensions: 1) AIHT’s
distinctive features; 2) their systemic impacts on health care and the health sector; 3) the
increased expectations towards AI in health; 4) the new ethical, social and legal challenges
that arise from deploying AI in the health sector; and 5) the new evaluative constraints that
AI poses to HTA. Thus, AIHTs are perceived as exceptional because of their technological
characteristics and potential impacts on society at large. As AI implementation by
governments and health organizations carries risks of generating new, and amplifying
existing, challenges, there are strong arguments for taking into consideration the
exceptional aspects of AIHTs, especially as their impacts on the healthcare system will
be far greater than that of drugs and medical devices. As AIHTs begin to be increasingly
introduced into the health care sector, there is a window of opportunity for HTA agencies
and scholars to consider AIHTs’ exceptionalism and to work towards only deploying
clinically, economically, socially acceptable AIHTs in the health care system.
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INTRODUCTION
Health technology assessment (HTA) is key to the introduction of
artificial intelligence (AI) applications in health. HTA generally
requires a systematic examination of health technologies’ features,
effects, and/or impacts allows for the appraisal of clinical,
economic, social, organizational and ethical implications (Banta
and Jonsson 2009; Kristensen et al., 2017; O’Rourke et al., 2020).
While regulatory assessment often is conducted by supranational
(e.g., European Medicines Agency, EMA) and national (US FDA,
Health Canada) regulators, HTA is mostly conducted at regional,
provincial or state-based level and represents the main gateway for
a health technology (e.g., drugs, vaccines, medical devices) to be
widely administered to patients (Vreman et al., 2020; Wang et al.,
2018). A health technology that is positively evaluated by a health
regulator or an HTA agency signals significant support for its use,
causing clinicians, patients, hospital administrators and third-party
payers (such as public or private health insurers) to consider
deploying and reimbursing this technology in their health care
system or setting (Allen et al., 2017;Wild, Stricka, and Patera 2017).
However, AI is not just another health technology, and many
commentators view its assessment as complex and particularly
challenging (Harwich and Laycock 2018; Mason et al., 2018; Shaw
et al., 2019). For instance, AI health technologies (AIHT)
implementation within the healthcare system is often done in a
fairly short timeframe after their development (months rather than
years as for drugs and vaccines), with the result that there is not yet
as much evidence of their effectiveness and impacts as would be
required by traditional HTA for many other health technologies
(Babic et al., 2019). Moreover, AI systems deployed within the
healthcare system continue to learn and evolve over time based on
the data they process (Reddy 2018); this is in contrast, for example,
with drugs whose formulation, dosage and routes of administration
are regulated, and to be modified for use in clinical context and
service delivery, often require new approval by HTA. In addition,
AI systems require to be trained on and use vast amounts of
(potentially sensitive) data (about patients, research participants,
clinicians, managers, health care systems, etc.) that raise issues of
privacy, (cyber)security, informed consent, data stewardship and
control over data usages (Wang and Preininger 2019; Dash et al.,
2019; Sun and Medaglia 2019; Bartoletti 2019).
The application of AI in health is expected to transform the way
we diagnose, prevent and treat as well as the way we interact with
technologies (Patel et al., 2009; Hamet and Tremblay 2017; The
Lancet 2017). This may advance healthcare by enhancing efficiency
by automatizing routine tasks and decreasing health-related costs
(Shafqat et al., 2020), broadening access to healthcare delivery
(Harwich and Laycock 2018), targeting more precisely patient
needs (Jameson and Longo 2015), and assisting clinicians in
their decision-making (Lysaght et al., 2019; Smith 2020). For
these benefits to materialize, governments and health authorities
must efficiently regulate AI, and conduct appropriate health
technology assessment (HTA). However, the very definition of
AI in health is still the subject of discussion, debate and negotiation
among both researchers and government authorities. AI in the
health sector can be broadly defined as a field concerned with the
development of algorithms and systems seeking to reproduce
human cognitive functions, such as learning and problem-
solving (Tang et al., 2018) with (current and anticipated) uses
that include (without being limited to) supporting medical
decision-making (Ahmed et al., 2020), pharmacovigilance
(Leyens et al., 2017), and prediction and diagnosis
(Noorbakhsh-Sabet et al., 2019). In fact, some AIHTs have
already been approved by the FDA, such as AI-powered devices
to diagnose eye diseases (Samuel and Gemma Derrick 2020). Risks
and harms of AI in healthcare are described at all levels, from the
clinical encounter (e.g., adverse effects of an AIHT that can spread
to entire patient populations, inexplicability of anAI-basedmedical
decision, issues with assigning responsibility for adverse events,
and patients’ loss of trust in their provider) to society as a whole
(e.g., furthering inequalities due to algorithm training on biased
data) (Sparrow and Hatherley 2019). Interestingly, one indication
that current HTA processes are not yet well adapted is the fact that
a significant number of AIHTs are benefiting from regulatory fast-
track and do not undergo HTA review, a situation that is
particularly noticeable in the United States (Benjamens et al.,
2020; Gerke et al., 2020; Tadavarthi et al., 2020).
Even though AI solutions offer great potential for improving
efficiency, health organizations are confrontedwith a vast array of AI
solutions that have not yet been subject to extensiveHTA (Love-Koh
et al., 2018). Moreover, many authors have highlighted that these
new technologies challenge traditional evaluation processes as well
as the assessment of the ethical, legal and social implications (ELSI)
that AIHTs may entail (He et al., 2019; Racine et al., 2019; Shaw
et al., 2019; Ahmad et al., 2020; Benjamens et al., 2020), thus further
impeding the already insufficient evaluative processes of AI health
technologies (AIHTs). To inform and support HTAorganizations in
adapting their evaluation processes to AIHTs, we conducted a
systematic review of the literature on the ethical, legal and social
challenges posed by AIHTs in HTA. The present article was guided
by this question: what makes artificial intelligence exceptional in
health technology assessment? To our knowledge, this is the first
review on this topic. After describing the methodology of the review,
we will provide a comprehensive overview of AI-specific challenges
that need to be considered to properly address AIHTs’ intrinsic and
contextual peculiarities in the context of HTA. This will lead to point
possible explanations of this exceptionalism and solutions for HTA.
Overall, this review is intended to build insights and awareness and
allow to inform HTA practices.
METHODOLOGY
To map the exceptional challenges posed by AIHTs in HTA, we
conducted a literature search for articles indexed in PubMed,
Embase, Journals@Ovid, Web of Science and the International
HTA database. Our review is part of a larger literature review
addressing the full range of ethical, legal, social and policy
implications that impact HTA processes for AIHTs. Therefore,
the search strategy focused on three concepts: AI, HTA and ELSI.
Table 1 presents the search equations by theme for each reviewed
database. In terms of definition of AI, we sought to remain
agnostic and did not use specific definitions of AI. Instead, we
used an inductive approach using a series of keywords (see
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Table 1) to identify and collect articles that mention using or
discussing AIHTs. The construction of the research strategy and
the choice of equations was supported by librarians.
The initial search (as of December 27, 2020) returned a total of
366 articles, which were uploaded in Covidence. JCBP and VC
conducted a careful analysis of the titles and abstracts that lead to
TABLE 1 | Search strategy.
Concepts Terms
AI PB  [(Artificial Intelligence) OR (Machine Learning) OR (Deep Learning) OR (Natural Language Processing) OR (Chatbot*)
OR (Carebot*) OR (Big Data)]
OR
[Artificial intelligence OR Big Data (MeSH Terms)]
EM; OJ; WoS  (Artificial Intelligence) OR (Machine Learning) OR (Deep Learning) OR (Natural Language Processing) OR
(Chatbot*) OR (Carebot*) OR (Big Data)
iHTAd  (Artificial Intelligence)
AND
HTA PB  (Health Technology Assessment) OR (HTA) OR (Technology Assessment)
OR
[Technology Assessment, Biomedical (MeSH Terms)]
EM; OJ; WoS  (Health Technology Assessment) OR (HTA) OR (Technology Assessment)
iHTAd  [Empty]
AND
ELSI PB  (ESLI) OR (Ethic*) OR (Bioethic*) OR (Moral*) OR (Legal*) OR (Law) OR (Societ*) OR (Polic*) OR (Governance) OR (Trust)
OR (Mistrust) OR (Jurisprudence) OR (Public Policy)
OR
(Bioethics OR Ethics OR Jurisprudence OR “Public Policy” [MeSH Terms])
EM;OJ;WoS  (ESLI) OR (Ethic*) OR (Bioethic*) OR (Moral*) OR (Legal*) OR (Law) OR (Societ*) OR (Polic*) OR (Governance)
OR (Trust) OR (Mistrust) OR (Jurisprudence) OR (Public Policy)
iHTAd  [Empty]
Legend. PB  PubMed; EM  Embase; OJ  Journals@Ovid Full Text; Databasel; WoS  Web of Science; iHTAd  International HTA.
TABLE 2 | Selection criteria.
Specifics
Date 2016–2020 (5 years)
Language English; French
Study design Descriptive; Experimental; Opinion/Perspective; Empirical Research; Literature Review
Type of publication Original research; Commentary; Editorial
FIGURE 1 | PRISMA Flowchart. AI  artificial intelligence; ELSI  ethical, legal, and social implications; HTA  health technology assessment.
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excluding 307 articles, and JCBP conducted the subsequent
analysis of main texts allowed to select 29 articles for review
(see Table 2 for selection criteria). In case of doubt or ambiguity,
articles were discussed with MCR to decide on inclusion or
exclusion. In addition to this sample, in January 2021, a
snowball process helped identify 17 additional papers that
fitted the selection criteria. Figure 1 presents our review
flowchart following PRISMA’s guidelines (Moher et al., 2009).
Documents were thematically analyzed (Braun and Clarke 2006)
with the help of NVivo 12. In the present article, we focus on the
theme “exceptionalism of AI in HTA”. Additional themes will be
published in subsequent papers.
RESULTS
What follows is a presentation of the key considerations that have
been raised in the reviewed literature regarding AI’s peculiarities,
and the challenges they raise, in the context of HTA. Twenty eight
articles from the total sample discussed these peculiarities and
challenges, which are presented as exceptional features of AI by
authors. The “exceptionalism” of AIHTs can be broken down into
five main aspects (see Figure 2): 1) AIHT’s distinctive features; 2)
their systemic impacts on health care and the health sector; 3) the
increased expectations towards AI in health; 4) the new ethical,
social and legal challenges that arise from deploying AI in the
health sector; and 5) the new evaluative constraints that AI poses
to HTA. Table 3 presents a summary of the key considerations
for each aspect.
Artificial Intelligence Health Technologies’
Distinctive Features FromTraditional Health
Technologies
AIHT’s exceptionalism is associated with the technology’s
definitional and foundational nature. Distinctive features
include AIHTs’ ambiguous definition; the fact that AIHTs
may or may not continue to evolve; and the need to keep
AIHTs up to date to reap the benefits and avoid the risks
of harms.
Ambiguous Definition of Artificial Intelligence Health
Technologies
According to Gerke et al. (2020), AIHTs are different from
traditional health technologies for three reasons: their capacity
to continuously learn, their potential for ubiquity throughout the
health care system, and the opaqueness of their
recommendations. However, AIHTs suffer from ambiguities
FIGURE 2 | The five main aspects of artificial intelligence health technologies’ exceptionalism.
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1. AIHT’s Distinctive Features from
Traditional Health Technologies
AIHTs are different from traditional health technologies because
of their capacity to continuously learn, their potential for ubiquity
throughout the health care system, the opaqueness of their
recommendations and the ambiguity of their definition
(Ambiguous Definition of AIHTs)
Locked AIHTs could become outdated potentially from the
moment they are prevented from evolving. Thus, locking AIHT
may cause it to become outdated and increase chance of
contextual bias in real-life contexts
Locked algorithms will always yield the same result when it is fed
by the same data. They are not per se safer and may require new
regulatory approvals, though they are easier to assess than
unlocked algorithms. Unlocked or adaptive algorithms improve
over time, which demands that their safety and security must be
continually re-evaluated. ‘Lifecycle’ regulation seems to be key in
addressing these concerns, but for the most part burden lies on
the regulators to adjusted their assessment of an AIHT in light of
the evolving evidence, which is very resource intensive and for
which HTA agencies are not yet equipped to conduct. (Locked
and Unlocked AIHTs)
Algorithms will need to be regularly updated (at high or even
prohibitive prices) due to advances in medical knowledge and
access to new datasets or at the risk of their usage becoming
malpractice. Updating or replacing an AIHT will involve additional
post-acquisition costs to the clinics and hospitals that purchased
them. The difficulty of managing the consequences of an outdated
algorithm outweighs those of a drug or other health product that
must be withdrawn from the market (The Update Problem)
2. Systemic Impacts on Health AI may have systemic effects that can be felt across an
entire health care system, or across health care systems in
several jurisdictions, initiating extensive and lasting
transformations that are likely to affect all actors working in,
using or financing the health system. In addition, AIHTs can
have systemic real-world consequences for patients and
non-ill or non-frequent users of the health care system.
However, AI will not address everything that has to do with
the overall well-being of people (Disruptive for Both the
Healthcare Sector and for Individuals)
AI’s role in health surveillance, care optimization, prevention,
public health, and telemedicine will cause AIHTs to affect non-ill
or non-frequent users of the health care system
An AIHT trained on medico-administrative data in a context
where physicians have often modified their billing to enter the
highest paying codes for clinical procedures would cause the
algorithm to infer that these codes represent the usual, standard,
or common practice to be recommended, thus introducing a
bias in the algorithm and leading to a cascade of non-cost
effective recommendations
Mistakes due to AIHTs used in clinical care and within the health
care system have the potential to widely affect the patient
population, suggesting that it is all the more necessary that all
algorithms should submitted to extensive scrutiny. In addition,
“tropic effects” (i.e., code embedded propensity towards certain
behaviors or effects) may increase the risk of inappropriate
treatment and care, and may result in importing AIHT-fueled
standards and practices that are exogenous and non-
idiosyncratic to local organizations. Furthermore, the large-scale
systematization of certain behaviors may end up resulting in
significant costs and harms (Harms, Tropism and Framing Effect)
Some authors suggest AIHTs should be regarded as a “health
system transformation lever” for improving health care and a key
enabler of learning healthcare systems (LHS) (AI as a
Transformation Lever for the Health Sector)
3. Increased Expectations The “automation bias” describes the belief that an AI-generated
outcome is inherently better than a human one. This is reinforced
by the technological imperative, i.e., the pressure to use a new
technology just because it exists (Belief that Since a Result
Comes from AI it is Better)
These high expectations toward AIHTs form the basis of the
inevitability of AI in health. However, the concept of AI chasm
refers to the phenomenon that while AIHTs are very promising,
The adoption and impact of AIHTs are unlikely to be uniform or to
improve performance in all health care contexts because of the
technology’s distinctive features, its systemic effects on health
care organizations and the human biases associated with the
use of these technologies. AIHTs can significantly affect and
highlight particularities of workflow and design of individual
hospital systems, causing them not to respond in an intended
way. Therefore, AIHTs represent great challenges for deciding
whether marketing authorization is justified
(Continued on following page)
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with respect to their definition and purpose as there is no agreed-upon
definition that may help build an adapted and efficient policy and
regulatory infrastructure (Pesapane et al., 2018). The drawback of AI
exceptional features and of the high variability that exists among AI
systems is that it poses definitional problems that affect AIHTs’
regulation and slow down their deployment in the healthcare
sector (Love-Koh et al., 2018; Haverinen et al., 2019). Compared
with traditional health technologies (such as drugs, vaccines and
medical devices), AIHTs are not static products and have the
capability to learn and improve over time (Parikh, Obermeyer, and
Navathe 2019; Dzobo et al., 2020). AIHTs are therefore in stark
contrast with most technologies in medicine, which are fairly
well defined and usually implemented when they are fairly well
understood.
Locked and Unlocked Artificial Intelligence Health
Technologies
Contributing to the distinctiveness of AIHTs in the health sector,
self-learning and self-adaptation propensities clash with current
regulatory frameworks and clinical practices (Alami et al., 2020;
Fenech et al., 2020). It is easier to evaluate “locked”AIHTs, which
are much more comparable to current health technologies (which
cannot by themselves evolve). Currently, the majority of FDA-
approved AIHTs have their capability to evolve locked (Dzobo






very few will actually be successful once implemented in clinical
settings and can help rebalance the expectations. HTA agencies
have an important role to play here to contain this phenomenon
(Inevitability of AI in Healthcare)
AI is currently in an era of promises rather than of fulfillment of
what is expected from it. Possible consequences of this hype can
be very significant but HTA agencies and regulators have an
important role to play (Navigating the Hype)
4. New Ethical, Legal and Social
Challenges
AIHTs present new ethical, legal and social challenges in the
context of health care delivery; by calling into question the roles of
patients, HCPs and decision-makers; and by conflicting with
medicine’s ethos of transparency
Patients who compare very well with historic patient data will be
the ones benefiting the most from AIHTs, calling for caution with
regards to patient and disease heterogeneity
Key AIHT-stemmed ethical challenges in care delivery are: AI-
fostered potential bias; patient privacy protection; trust of
clinicians and the general public towards machine-led medicine;
new health inequalities (Health Care Delivery)
Practical and procedural ethical guidance for supporting HTA for
AIHTs has not yet been thoroughly defined. For instance,
distributive justice role in HTA for AIHT is not well specified
AI being unlike most other health technologies, it forces the
questioning of the very essence of humans. It also raises new
existential questions regarding the role of regulators and public
decision-makers AIHTs unparalleled autonomy intensifies ethical
and regulatory challenges (Existential Questions)
AI-stemmed existential questionning includes the reflection that
more and more clinicians are having about the proper role of
healthcare professionals and what it means to be a doctor, a
nurse, etc. And from the patients’ perspective, what it means to
be cared for by machines and to feel more and more like a
number in a vast system run by algorithms
AIHTs are often opaque, which poses serious problems for their
acceptance, regulation and implementation in the health care
system. AI’s benefits for health care will come at the price of
raising ethical issues specific to the technology (Challenging
Medical Ethics’ Ethos)
5. New Evaluative Constraints AIHTs raise new evaluative constrains at the technological level
due to the data and infrastructure required (Data-Generated
Issues)
New constraints also appear at the clinical level because of the
greater variation in AIHTs performance between the test
environment and the real-word context than those of drugs and
medical devices (Real-World Usages and Evidential Issues)
The adoption and impact of AIHTs are unlikely to be uniform or to
improve performance in all health care contexts because of the
technology’s distinctive features, its systemic effects on health
care organizations and the human biases associated with the
use of these technologies. Therefore, AIHTs represent great
challenges for deciding whether marketing authorization is
justified, and it forces to question whether marketing
authorization at the 10,000 foot level for the product is
appropriate and efficient as opposed to for more specific uses
closer to the impacted communities and the point of deliveryThis high level of complexity requires a special regulation of AIHT,
specifically adapted to its complexity (Undeveloped Regulatory
Infrastructure and Processes)
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et al., 2020; Miller, 2020). A locked algorithm will always yield
the same result when it is fed by the same data, therefore it
does not change overtime with uses. Locked algorithms are not
per se safer. They could be more harmful than “unlocked” or
“adaptive” algorithms if they end up yielding erroneous results
(based on legacy training data that are outdated), misleading
patient care or systematizing biases (Prabhu 2019). Thus, a locked
AIHT may require new regulatory approvals if during real-
world usage significant and unexpected patterns of results
are observed (i.e., stable and expected process produces
outcomes unexpected because of incorrect priors about the
data fed into an AIHT) or if it is deemed necessary to update
the algorithms to match advances in medical knowledge
(Gerke et al., 2020; Miller, 2020). There also is the issue of
when AIHT is used (or not used) on new populations that
differ from the training data, which raises questions about how
the training data upon which an AIHT was developed and
whether certain populations may be unduly excluded from
benefiting from its development and implementation.
Therefore the concept of locked may be misleading and
should not be conveyed as safer (Babic et al., 2019).
Unlocked or adaptive algorithms that improve over time is
the future according to some (Prabhu 2019) as they will
outperform humans (Dzobo et al., 2020). But some issues
are to be expected. Unlocked AIHT may change as they
process new data and yield new outcomes without the
knowledge or oversight of its users, which demands that
their safety and security must be continually re-evaluated
(Abràmoff et al., 2020). Also, unlike traditional healthcare
technologies and locked algorithms, unlocked AIHTs are more
vulnerable to cyber-attacks and misuse that can cause the
algorithm to generate problematic and highly damaging
outputs (Babic et al., 2019; Miller, 2020).
The Update Problem
Another consideration that helps AIHT qualify for being an
anomalous technology in the health sector is that the
algorithms will need to be regularly updated (at high or even
prohibitive prices) due to advances in medical knowledge and
access to new datasets or at the risk of their usage becoming
malpractice. To allow a rigorous analysis of the safety, efficiency,
and equity of a given AIHT, it is necessary that the locked or
unlocked state of the algorithm is always known to regulators and
end-users (Char et al., 2020). Such transparency is necessary
since due to the very distinct ethical and clinical implications
that locked or unlocked AIHTs may generate. The update
problem implies that a locked AIHT could quickly become
outdated—potentially from the moment it is prevented from
evolving (with or without supervision)—and that this could
generate important risks as a result of the deployment and use
of AIHTs in real-life contexts (Abràmoff et al., 2020). Although
not all algorithms may need to evolve or be updated in the short
term, at some point in time, updating or replacing an AIHT will
involve additional post-acquisition costs. Post-acquisition
updates and costs may seem counter-intuitive considering the
distinctive characteristics attributed to AI, such as self-learning
and continuous improvement. This may lead for certain
organizations (in particular, in less affluent contexts or in
periods of economic turmoil) not to deploy updates which will
result in the uses of outdated algorithms and therefore sub-
optimal benefits (if not harms) for some patients or services
(Prabhu 2019). Since AIHT are considered as being more
pervasive than physical technologies (such as drugs and other
health products), some are arguying that managing the
consequences of an outdated algorithm outweigh those of
traditional health technologies (Babic et al., 2019; Prabhu
2019); even if it is very difficult to withdraw effectively a drug
from the market, it is still possible to do so, while it may be much
more challenging for AIHTs that are less visible, interpretable and
tangible and more likely to be embedded in a hospital’s or health
system’s IT systems.
Systemic Impacts on Health
Characteristic of disruptive technologies, AIHTs are said to have
significant and systemic impacts on the healthcare sector. From
the outset, what emerges is that AI has a capacity for
information analysis that surpasses what is currently
available from health professionals, healthcare managers or
even from learning health systems (LHS) (Cowie 2017;
Pesapane et al., 2018; Char and Burgart 2020). AI is geared
towards changing healthcare practices by facilitating a better
integration of innovations and of best practices that will yield
optimal care delivery (Grant et al., 2020). These systemwide
impacts may lead to both risks of harms and opportunities to
optimize the health care system that must be taken into
consideration in HTA.
Disruptive for Both the Healthcare Sector and for
Individuals
Contrary to many health technologies, AI may have systemic
effects that can be felt across an entire health care system, or even
more so across health care systems in several jurisdictions (Dzobo
et al., 2020). Gerhards et al. (2020) go as far as stating that AIHTs
(especially those using machine learning) can yield significant
changes to an entire healthcare system. These changes might not
necessarily come from expected technological disruptions, but
might come from the adaptation of the healthcare setting to
certain methods and processes relying on AIHTs. This adaptation
may initiate extensive and lasting transformations that are likely
to affect all actors working in, using or financing the health
system (Gerhards et al., 2020). The clinical use of some AIHTs
may have the effect of transforming local health care
administration practices by incorporating exogenous priors
embedded within the technology. For instance, if a payer
(public or private insurer) decides that a given AIHT
recommendation become a precondition for reimbursement
(i.e., making other care no longer reimbursable), this may
have significant impacts on the way care is delivered, and will
reduce patients’, clinicians’ and administrators’ autonomy in
making shared and appropriate decisions when the human-
recommended care is different than a new gold standard based
on AI on data and priors (Vayena, Blasimme, and Cohen 2018).
There is therefore a process of importing practices, potentially
very different, which can strongly contrast with local habits and
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norms, requiring both adaptation and an impact assessment of
these exogenous practices on the host environment.
AIHTs can have systemic real-world life-and-death
consequences for patients (Miller, 2020), especially as AI
will span across the life continuum from birth to death
(Dzobo et al., 2020). AIHTs, unlike most drugs or medical
devices, will also affect non-ill or non-frequent users of the
health care system, be they due to AI increasing role in health
surveillance, care optimization, prevention and public health,
telemedicine (Love-Koh et al., 2018; Pesapane et al., 2018;
Char and Burgart 2020). AI can help “democratizing health
care” (i.e., in the sense of facilitating access) by extending care
into patients’ homes (Reddy et al., 2020), places where more
individualized and personalized care can be facilitated. While
being increasingly present in patient care, AI will not address
everything that has to do with the overall well-being of people.
Some aspects less related to illness, such as spirituality and
sociality, will most likely not be resolved and supported by AI
systems (Dzobo et al., 2020). Therefore, a systematic response to
using AI in health care may systemically neglect important
aspects of care.
Harms and Tropism
Mistakes due to AIHTs used in clinical care and within the health
care system have the potential to widely harm the patient
population. Some AI systems, especially in primary care
settings, can have impacts on the entire population of a
hospital or clinic (such as an AI-powered patient triage). This
makes some people say that it is all the more necessary that all
algorithms should be submitted to extensive scrutiny, with an
increased attention on validation in clinical settings before they
can be deployed in medical practice (Dzobo et al., 2020). In
addition, a key challenge in implementing AI is that, without a
comprehensive understanding of health needs (especially those
not covered by AI), there is a risk of fragmenting healthcare
delivery by silo use of AI systems. Such silo use may lead to
weakening health systems capacity and efficiency in addressing
patients needs.
AIHTs can have tropism effects on the healthcare system that
may shape and normalize certain practices and expectations that
are not necessarily accepted, widespread, cost-effective or
standard in new contexts. An example of this would be an
AIHT trained on medico-administrative data in a context
where physicians have often modified their billing to enter the
highest paying codes for clinical procedures, causing the
algorithm to infer that these codes represent the usual,
standard, or common practice to be recommended (Alami
et al., 2020). Thus, the algorithmic inference would be biased
because the procedure billed maximizes the clinician’s
remuneration, but potentially was not the one performed; this
can lead to a cascade of non-cost effective recommendations.
Such tropism effects may increase the risk of inappropriate
treatment and care, and may result in importing AIHT-fueled
standards and practices that are exogenous and non-idiosyncratic
to local organizations and that may perpetuate latent biases in
training data that are not present in certain health systems or
contexts of care (Abràmoff et al., 2020; Alami et al., 2020; Miller,
2020). Therefore, the large-scale systematization of certain
behaviors or inclinations may end up resulting in significant
costs and harms for organizations and health systems as well for
patients and HCPs (Alami et al., 2020; Hu et al., 2019). For
example, higher sensitivities to clinical thresholds could lead to
overdiagnosis or overprescription, while lower sensitivities could
result in undiagnosed and untreated segments of the population;
it is in the potential scope of the impacts that exceptionalism lies
and must be carefully assessed in HTA (Alami et al., 2020; Topol
2020).
AI as a Transformation Lever for the Health Sector
According to Alami et al. (2020), instead of seeing AIHTs as a
collection of distinct technologies, they should be regarded as a
“health system transformation lever.” AI can serve as a strategic
lever for improving health care and services access, quality and
efficiency. Used in such way, AI could have significant society-
wide impacts, including technological, clinical, organizational,
professional, economic, legal, and ethical.
AI can become a key enabler of learning healthcare systems
(LHS) to achieve their full potential (Babic et al., 2019), especially
since AIHTs are themselves learning systems (Ho, 2020). AIHTs
and LHS can complement each other as both strive when there
are porous boundaries between research and development and
with clinical and organizational practices. Using data from the
health care system, AI can learn and recalibrate both its
performance and behaviors, and over time inform and refine
the practices of the health care system (Babic et al., 2019). AI can
allow for ongoing assessment of accuracy and usage and
continuous risk monitoring (Ho, 2020).
AI, as a lever, can also have a systemic impact of putting
forward the response to needs for which there are ready-to-use
technologies, causing to pay little attention to serious unmet
needs (Alami et al., 2020). According to Grant et al. (2020), AI
may represent the “next major technologic breakthrough” in
health care delivery, offering endless possibilities for improving
both patient care and yielding health care system-wide
optimizations. However, this blurring of boundaries poses
significant problems for adequate regulatory design and should
not be taken lightly (Babic et al., 2019).
Increased Expectations Towards Artificial
Intelligence
Another key feature of AI exceptionalism is the increased
expectations placed on AIHTs compared to other health
technologies. According to Vollmer et al. (2020), AI systems
often bear a misleading aura of obvious cutting-edge technology,
which falsely limits the perceived need for careful validation and
verification of their performance, clinical use, and general use
once they begin to be used in routine clinical practice. The
implications for HTA are three-pronged.
Belief that Since a Result Comes From an Artificial
Intelligence It Is Better
A large part of the explanation for AI exceptionalism comes in
particular from the belief that an AI-generated outcome is
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inherently better than a human one (Char and Burgart 2020).
This phenomenon, known as the automation bias, describes the
fact that slowly but surely, AI is establishing itself as an authority
over current practices and error-prone healthcare professionals.
Part of this is reflected in the fact that it is now recognized as a
problem that a person who disagrees with a result or
recommendation generated by an AI must justify their
opposition with much more data than those used by the AI to
achieve that result (Char and Burgart 2020). The technological
imperative—i.e., the mere fact that a sophisticated technological
intervention exists creates pressure to use it because it is perceived
to be superior to conventional practices, despite the
risks—reinforces this belief and AI in medicine is currently
having its technological imperative moment (Carter et al., 2020).
Inevitability of Artificial Intelligence in Healthcare
These high expectations toward AIHTs form the basis of the
inevitability of AI in health. To the point where AI is seen as
inevitably the future of medicine (Dzobo et al., 2020). Self-
learning and the ability to perform arduous and repetitive
tasks explains the growing interest for a greater place of AI in
standard medical care. There are high hopes and, according to
many commentators, good reasons to think that in a near future,
virtually all physicians will be assisted by AI applications to
expedite certain tasks and, in the median term, due to
continuous learning, AIHTs might outperform humans in a
wide range of areas (Dzobo et al., 2020; Abràmoff et al.2020;
Gerke et al., 2020). It is not only for clinical or therapeutic reasons
that AI seems to be inexorable; there is also competition within
the AI ecosystem. The growing importance of AI and its
inevitability also stems from the competition between political
decision-makers from different jurisdictions to widely deploy AI
in order not to lag behind others (Gerhards et al., 2020).
Considering all the interests at stake, the massive investments
and accelerated development of AI, the question is no longer
whether AI will be part of routine clinical care, but when (Reddy
et al., 2020).
Although the technological imperative is strong and that AI in
health is very attractive and seems inevitable, caution is called for.
In this regard, AI chasm is a powerful concept to rebalance and
help manage expectations of overly rapid deployment and
ubiquity of AI in health care (McCradden et al., 2020). AI
chasm refers to the phenomenon that while AIHTs are very
promising, very few will actually be successful once implemented
in clinical settings. HTA agencies have an important role to play
here to contain this phenomenon and reduce its frequency and
spread (McCradden et al., 2020). One of the roles of evaluation
and regulation is precisely to finely consider the implications of
these technologies to overcome this phenomenon. This requires
not only an analysis of technical efficiency and performance, but
also an oversight of empirical and ethical validation to ensure the
rights and interests of patients. This requires the development of
regulatory tools that are well adapted to AIHTs so that there are
clear procedures and processes to properly evaluate and screen
AIHTs (Alami, Lehoux, Auclair, Guise, et al., 2020; Abràmoff
et al., 2020). This is necessary to avoid ethical drifts and
unacceptable (economic, health, social) costs that may be
caused by technologies that are not adapted to the needs and
specificities of a clinical or organizational context, or by milieus
feeling pressure to deploy a technology and adapt its practices in a
way that ultimately does not benefit patient care or sound health
care management (Michie et al., 2017; Abràmoff et al.2020).
Navigating the Hype
AI is currently in an era of promises rather than of fulfillment of
what is expected from it (Michie et al., 2017). This new science
has yet to move beyond average outcomes on individuals to actual
personalized benefits based on their situation, characteristics, and
desired outcomes. It is important to remain critical and vigilant
with respect to the rush to adopt these new technologies, possibly
more so than politicians are at present (Cowie 2017). Especially
when thought leaders’ perspectives echo public wonderment and
aspirations that AI transforms human life (Miller, 2020). With
their development and implementation being largely driven by a
highly speculative market and by proprietary interests, AIHTs are
largely embedded into biocapital (Carter et al., 2020). That is to
say, a vision of medical innovation that is based not on the actual
creation of value, but on selling a certain vision of the future. It is
through the sale of imaginary evoking unparalleled performance
and disproportionate benefits to encourage all AI players to
engage in the massive implementation of AI despite its
uncertainties and shortcomings (Carter et al., 2020). That
being said, in a study reported by Vayena et al. (2018), half of
the surveyed American healthcare decision-makers expect that
AIHTs will both improve medicine and fail meeting hyped
expectations. Miller (2020) sums up the present phenomenon
as follows: “No matter how sanguine the gurus touting game-
changing AI technologies are, and no matter how much
caregivers and patients hope that their benefits to medical
practice and outcomes are not hype, all parties must remain
vigilant.”AIHTs are in their phase of promises and hype, which is
creating inconsequent expectations (Reardon 2019).
The consequences of these unreasonable expectations can be
very significant. For instance, patients’ unsound expectations
regarding the clinical outcomes of AIHTs can negatively affect
their care experience (Alami et al., 2020). Certain areas of care,
such as breast cancer, are particularly fertile ground to AI
companies’ hype and promises (Carter et al., 2020), because
it resonates with patient unfulfilled demands. The
counterweight to these expectations is not yet in place as,
despite all the hype, the science of AI is still young and
possibly not yet mature, including gaps in clinical validation
and perhaps imprecise health recommendations (Dzobo et al.,
2020). HTA agencies and regulators have an important role to
play, particularly in developing a regulatory infrastructure that
is as exceptional as technology can be for health and as powerful
as the “unfounded hype” can be, to use Mazurowski (2019)
expression.
New Ethical Challenges
There seems to be broad agreement that AIHTs present new
ethical challenges (Vollmer et al., 2020). According to Michie
et al. (2017), AIHTs presents “new challenges and new versions of
old challenges” which require new evaluative methods and
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legislative motivation to address health data and AIHT-specific
ethical and regulatory issues.
Health Care Delivery
Reddy et al. (2020) identified three key AIHT-stemmed ethical
challenges in care delivery: AI-fostered potential bias, patient
privacy protection and trust of clinicians and the general public
towards machine-led medicine. AI is also prone to generating
new health inequalities; perhaps more potent than its ability to
reduce existing ones (Fenech et al., 2020). An important caveat in
terms of health care equity comes from the fact that those who
compare very well with historic patient data will be the one
benefiting the most from AIHTs. A cautious attitude is therefore
called for with regards to patient and disease heterogeneity, taking
into account that patterns detected by AI are largely deduced
from smaller historical data sets (Dzobo et al., 2020). In addition
to the current disparities, digital literacy and access to
technologies are adding up, so that if nothing is done, large
segments of the population may be excluded from enjoying the
benefits of AIHTs, resulting in significant issues of justice (Fenech
et al., 2020).
Existential Questions
According to Fenech et al., 2020, AI is unlike any other health
technology, due to its capability of being a general-purpose
technology forcing to question the very essence of humans.
This technology is particularly sensitive for the healthcare
sector as it raises new existential questions that regulators and
public decision-makers must now face. One of such key
existential challenge for HTA, according to Haverinen et al.
(2019), is that AI is becoming a new decision-maker. This
adds an actor with a decision-making role on the fate of
patients and the health care system in addition to the role of
HCPs and increases the complexity of performing comprehensive
HTA. For Ho (2020), a distinctive ethical concern that stems from
AIHT is the technology’s unparalleled autonomy, which
intensifies ethical and regulatory challenges, especially in terms
of patient safety. While this obviously raises questions about
liability (who is at fault for harm, and who is responsible for
explaining it and being accountable to patients), it also requires
thorough thinking about appropriate ways to ensure that care is
humane and respects the dignity of persons (Pesapane et al., 2018;
Vayena et al., 2018; Fenech et al., 2020).
Challenging Medical Ethics’ Ethos
Exceptionalism also stems from the fact that the field of medicine
is structured around the transparency and explainability of
clinical decisions, which poses serious problems for the
acceptance, regulation and implementation of (too often
inexplicable) AI in the health care system (Reddy et al., 2020).
As Miller (2020) points out that technology insertion is never
neutral, both the success of AI in health care and the integrity and
reputation of health care professionals depend on the alignment
between the ethos of medical ethics and the ability of AIHTs
(notwithstanding its benefits and performance) to respond to the
challenges that its very characteristics pose to the health care
system (Reddy et al., 2020). It is therefore widely acknowledged
that AI will have considerable benefits on health care (optimized
process, increased quality, reduced cost, and expanded access)
that will come at the price of raising ethical issues specific to the
technology (Abràmoff et al., 2020). This moral cost and related
ethical considerations partly explain that the field of AI ethics has
recently “exploded” as academics, organizations and other
stakeholders have been rushing to examine the ethical
dimensions of AI development and implementation (Fiske
et al., 2020). However, some are skeptical, such as Fenech
et al. (2020) who was warning that data ethics is fashionable.
While Bærøe et al. (2020) go as far as arguing that “exceptional
technologies require exceptional ethics” and that “an intentional
search for exceptionalism is required for an ethical framework
tasked with assessing this new technology”.
New Evaluative Constraints
According to Dzobo et al. (2020), by being very distinct from
more traditional technologies, AI must be regulated differently.
Zawati and Lang (2020) argue that the uncertainty regarding AI
decisional processes and outcomes make AIHTs particularly
challenging to regulate. Regulators, policy-makers and HTA
agencies are faced with unprecedented complexity for
evaluating and approving AI (Alami et al., 2020). AIHTs raise
new evaluative constrains, be they technological, clinical,
organizational, that affect how ethical, legal and social
dimensions may be tackled (Gerke et al., 2020). Evaluation
constraints are related to data, real-world uses and the
embryonic nature of the regulatory infrastructure and processes.
Data-Generated Issues
AI uses larger than ever volumes of data generated by individuals,
governments, and companies, and according to Fenech et al.
(2020), the greater complexity of health data raise new questions
about the governance of data use and storage, especially as AI
technologies are only effective and relevant with up-to-date,
labelled, and cleaned big data. In addition to data, the
hardware infrastructure will need to be updated over time,
requiring major financial investments to maintain the use of
AI in the healthcare system (Dzobo et al., 2020). However, too few
technical studies are helping to appreciate and help managing
AIHTs’ complexity. In most studies, contextual, clinical and
organizational considerations, implementation and uses of the
technology are neglected, which complicates regulators’
assessment as they are mostly informed about the significance
of AI applications’ technical performance (Alami et al., 2020).
Caution should therefore be exercised, particularly since the
complex ethical and regulatory issues involved deserve careful
consideration before deploying these technologies in routine
clinical care (Prabhu 2019).
Real-World Usages and Evidential Issues
AIHTs raise new regulatory challenges in part due to the greater
variation in their performance between the test environment and
the real-word context than those of drugs and medical devices.
According to Gerke et al. (2020), AIHTs have potentially more
risks and less certainty associated with their use in real-world
contexts, which is central to regulatory concerns. However, most
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AIHTs have not been objectively validated in and for real-world
usages (Alami et al., 2020). In that sense, one important caveat is
that the adoption and impact of AIHTs are unlikely to be uniform
or to improve performance in all health care contexts (Gerke
et al., 2020). This is attributable concurrently to the technology
itself (and its distinctive features that renders it disruptive), to the
contexts of implementation (the systemic impact of the
technology across the health care system, and clash with local
practices) and to the human biases associated with the use of these
technologies (inability to reason with AI-provided probabilities,
small samples and noise induced extrapolation and false patterns
identification, and undue risk aversion) (Gerke et al., 2020). For
regulatory authorities, these represent great challenges for
deciding whether marketing authorization is justified. But it is
also puzzling for hospital, clinic and health care system
purchasers to determine whether an AIHT will actually add
value and increase performance of care and service delivery.
There is a lot to be studied and understood on the broad
systemic policy implications of AIHTs in real-world context of
care and services (Alami, Lehoux, Auclair, de Guise, et al., 2020).
Undeveloped Regulatory Infrastructure and
Processes
AIHTs’ exceptional characteristics have significant regulatory
implications as regulation is emerging, but at a far slower pace
than technological changes, which are virtually infinite (Char and
Burgart 2020). Regulative complexity is furthered by the fact that
existing standards (e.g., those of the Food and Drug
Administration, European Medicines Agency, Health Canada)
do not translate well for self-evolving technologies (Dzobo et al.,
2020; Shaffer 2020; Topol 2020). This definitional deficit
complicates the regulation of this technology and the
implementation of appropriate policy infrastructure (Pesapane
et al., 2018). Recent approvals of algorithms highlighted some
limitations of existing regulatory standards and processes
(Haverinen et al., 2019; Parikh et al., 2019). These
considerations are threefold and concern the levels of
requirements, the speed of AIHT developments and the
equilibrium posture that regulators must adopt.
A challenge for existing regulatory regimes lies in the extensive
information requirements on both the nature and effects of health
technology, as well as clinical data on efficacy and patient safety,
and population and societal impacts. However, regulators have
yet to develop an infrastructure and processes that are
appropriate and optimal for AI, and this requires more
knowledge about how algorithms work (Dzobo et al., 2020).
This complicates the problem because AI is a less transparent
and explainable technology than drugs or medical devices can be
(Abràmoff et al., 2020; Reddy et al., 2020). Privacy concerns are
also important and there is yet no public agreement regarding
data collection and sharing for commercial purposes, nor
regarding for-profit data ownership (Michie et al., 2017). This
calls for finding collective responses to these considerations,
which must accompany the work of structuring HTA practices
and infrastructures by regulators (Fenech et al., 2020).
Another dimension putting pressure on regulation is the speed
of development. For regulating a fast-changing and unpredictably
sector such as AI, time is of the essence to ensure that regulatory
standards and practices are relevant (Pesapane et al., 2018).
Currently, regulation has to constantly catch up with the
private sector which leads to important gaps in terms of
ethical examination of AIHTs (Shaffer 2020). Since, most
developments are done by the private sector and HTA
processes are not yet well designed and optimized, there is a
problem of scrutiny (Abràmoff et al., 2020). So to keep up,
regulation must be as fast as technological developments in
AI, therefore it requires to conduct assessment and oversight
at an unprecedented pace (Haverinen et al., 2019). However, this
need to proceed quickly, in particular to match the private sector’s
pace, must be put into perspective with the very acceptability of a
significant presence of commercial interests in the big data and
AIHTs sector.
Achieving the right balance is delicate for HTA agencies
between accelerating the development of HTA policies and
procedures and not falling prey to the sirens of AIHT’s hype
(Cowie, 2017; Miller, 2020). Regulators want to see the health care
system reap AI’s benefits quickly, but if their assessment is too
hasty and the implementation of the first generations of AIHTs
encounters difficulties or, worse, generates adverse effects, social
and professional acceptability may be shattered and further delay
the deployment of AI in healthcare. According to Reddy et al.
(2020), it could need a single serious adverse incident caused by
an AIHT to undermine the public’s and HCP communities’
confidence. Considering that AI’s acceptance is still fragile,
and that AI is expected to have an expanded presence in all
aspects of the health care system, HTA agencies will have to be
extra careful in considering the ethical and regulatory
implications of IA. If not well managed, these considerations
will become major barriers that will play against the deployment
of AI in healthcare (Pilotto et al., 2018; Vayena et al., 2018; Bærøe
et al., 2020).
DISCUSSION
The current body of literature appears to portray AI health
technologies as being exceptional to HTA. This exceptionalism
is expressed along five dimensions. Firstly, the very nature of the
technology seems to be the primary cause of the difficulty in
fitting AIHTs into current HTA processes. Thus, the still
ambiguous definition and the consequences of its changing
and evolving nature pose new challenges for its assessment.
Secondly, the scope of its impact far surpasses those of current
health technologies. AIHTs will have impacts that extend
significantly beyond the targeted patients and professionals. It
is therefore in the interest of HTA agencies to consider the
disruptive effects on individuals as well as on the entire health
care system. Hence, the importance for HTA to consider the
potential harms, the systematization of biases and to anticipate
the clashes between current practices that are working well and
the framing effect that will come with the deployment of AIHTs.
But also, AI can act as a transformational lever that, beyond the
risks of AI in healthcare, appears to be capable of redressing and
reorienting the healthcare system to better respond to the full
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range of healthcare needs, to create synergies so that the of
learning healthcare systems are operational and to take this
opportunity to adjust the regulatory design. Third, the advent
of AI in healthcare comes with a lot of high expectations. The
quality of outcomes generated by AIHTs is expected to be higher
than that of current human-driven processes. This positive
perception of the added value of AIHTs in the healthcare
system makes AI in healthcare appear inevitable. However,
while the technology is currently casted as exceptional and
highly promising, some caution should be kept towards the
current hype, which should prompt regulators to be prudent
towards unreasonable expectations. Fourth, AIHTs are
challenging HTA from an ethical perspective as AI has a
strong potential to generate greater inequity whether arising
from algorithmic decisions or in access to AIHTs. The fact
that AIHTs are becoming new decision-makers, due to their
autonomy, raises important issues of patient safety as well as
liability. In fine, medical ethics’ ethos is even shattered since, with
AI, ethical dilemmas seem to be amplified, calling potentially for
ethical standards revamping that would be as exceptional as the
technology. Finally, AI technologies in health are increasing
regulatory complexity and are pressuring current HTA
structure and processes. The new evaluation constraints relate
to data, real-world uses and the rather embryonic nature of AI-
ready regulatory infrastructure and processes. Therefore, be they
the extensive information requirements on both AIHTs’ features
and effects for regulatory review, the speed of AIHTs’
developments, and the need to regulate quickly, but in a way
that benefits the entire population.
A key point emerging from the views of the authors reviewed is
that exceptionalising views of AIHTs, in the context of HTA,
appear to come as much from the technology itself as they do
from the broader social, cultural, and political contexts
surrounding AI in the health sector. In other words, AIHTs
are exceptional because of their technological characteristics and
potential impacts on society at large. This is quite consistent with
HTA, which seeks to assess the diversity of impacts of a
technology. It is therefore quite reasonable that a technology
with multi-dimensional impacts on society severely affects a
process that is based on these same dimensions. The key
takeaway may be that, to adapt and remain relevant, HTA
must continue to focus on and strengthen these evaluative
processes, which must be capable of a comprehensive
assessment of the technical, social, cultural, ethical and health
dimensions.
Interestingly, no author in the reviewed sample clearly
promoted the idea that AI is an unexceptional technology for
HTA. Many reasons could explain this phenomenon. First, the
hype is still very strong when it comes to AIHT (Mazurowski
2019; Carter et al., 2020). Thus, it is possible that discussions
about AI (un)exceptionalism are not yet ripe to mark the
literature. This can be seen in the literature reviewed, which,
without focusing on the limits of exceptionalism, currently has its
strongest criticisms on AI hype. This leads us to think that hype
and exceptionalism may be linked: hype feeds on exceptionalism
while the latter needs hype to surface and to strike a chord within
the literature and the rhetoric about AI in health. Second, trivially,
this may be because there is less incentive to write (and publish)
on the advent of a new technology in health by stating that
nothing is new under the Sun (Caulfield 2018). Third, AIHTsmay
be so recent in the HTA pipeline that HTA as not yet addressed all
the dimensions of AIHT.
Even if AI’s exceptionalism appears significant in the current
body of literature, there is some caveats to promoting AI
exceptionalism in HTA. First, two authors noted some
limitations to AI exceptionalism. Michie et al., (2017) pointed
out that AIHTs are not only raising new challenges, they also bear
issues that are common to existing health technologies. This is
echoed by Char et al. (2020) who acknowledge the phenomenon,
but puts a limit to the enthusiasm for AI exceptionalism in health
when it comes to AIHTs sporting some features similar to
standard health technologies. Second, currently, the literature
discussing AI exceptionalism is still piecemeal, and it would be
relevant for future research to address the issue by looking more
holistically at the full range of issues posed by AI (i.e., outside the
sole realm of HTA). There is still some space to apprehend and
analyze the exceptionality of AIHTs’ in HTA and the implications
this has for both the evolution of HTA and the development and
use of AIHTs. The literature is still quite young, and this can be
observed from the fact that some highly discussed considerations
in the broader AI ethics and AI in medicine literatures have not
been discussed in the body of literature at review. For example,
the more structural implications related to data-generated
issues—privacy, data stewardship and intellectual property
(Bartoletti 2019; Cohen and Mello 2019)—or to issues
pertaining to informed consent, patient autonomy and human
rights (Sparrow and Hatherley 2019; Cohen 2019; Racine et al.,
2019; Ahmed et al., 2020), or to human-machine comparison in
medical decision making and diagnosis (London 2019) have not
been explored in the studied subset. A comprehensive exploration
of the themes generally associated with health technologies will
provide a better understanding of and clarity on whether AIHTs
are exceptional or not. Third, exceptionalism in the context of
health innovation is not a new topic. New health interventions or
discoveries often generate a lot of hype, and the sector is hungry
for predictions about the next revolution in healthcare (Emanuel
andWachter 2019). Twenty years ago, the health sector was living
the “genomic revolution” and was assessing the exceptional
implications of genetics in healthcare (Suter 2001). As AIHT’s
literature mature, it may continue to be centered on its
exceptionality; but it is also plausible to consider that, as with
the genetic revolution in the early 2000s and the
nanotechnologies in the 2010s, AI exceptionalism will pass
what Murray (2019) calls its “sell-by date”. Thus, AI
exceptionalism may end up following a rather similar pattern
where the hype will slowly wear off as the health sector will
becomemore accustomed to the technology; better understand its
actual strengths, limitations, and capabilities.
Therefore, possibly it is a matter of time before a coherent
body of literature addresses the limits of an exceptionalist view of
AI in health and HTA. At the same time, if the AI revolution
really takes off, exceptionalism will no longer be an important
consideration. Indeed, as regulatory systems, the healthcare
system and human agents (clinicians, patients, regulators,
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managers, etc.) adapt, exceptionalism will probably pass and
habituation will make AI in health the new normal, as after
any major disruption that lasts over time. However, it may be of
interest to the AI, HTA and health regulation communities and
scholars to remain vigilant about AIHTs’ exceptionalism (by
means of the manifestation of its five dimensions) in health
and HTA.
Another avenue that the literature could explore is whether the
exceptionality arises from the technology (i.e., AI) or the sector of
application (i.e., health)? In other words, is it AI that is
exceptional in health or rather health that is a sector of
exception for AI? Healthcare is possibly the most regulated
sector that AI has come across so far. Health’s exceptionality
may explain the significant regulation in the healthcare sector
(i.e., attention given to this sector in terms of regulation, ethics,
law, and society) (Daniels 2001; Bird and Lynch 2019), while no
other sector has an assessment process that has the breadth and
systematism of HTA. Therefore, it would be interesting to reverse
the question at the very basis of this review and consider how, for
the AI ecosystem, health is per se exceptional and calls for
additional and distinct norms, practices and contingencies that
need to be considered to develop and implement an AIHT.
Thereby, in addition to offering insights and guidance to
communities strongly engaged in HTA, our results can also
help the AI research and development sector better
understand the unique evaluative considerations that exist in
the health sector. The five dimensions raised by our paper
can help guide those developing AIHTs to better understand
and respond to the specific expectations and priors that
underlie the use, administration and acceptability of health
technologies. This can potentially help better align AIHT
developers’ desire to create value with HTA agencies’ value
appreciation and thus facilitate the congruence between
technology development and healthcare priorities (Chalkidou
2021).
More broadly, the literature review raises key institutional
questions, in terms of the exceptional issues posed by AI, such as
which body is best placed to incorporate the new and added
concerns that AIHTs raise? Is it the (supra)national regulators
(e.g., EMA, FDA, Health Canada and the like which are mostly
responsible for evaluating safety, efficacy, and quality concerns)
or the HTA bodies (who are more concerned with appropriate
use, implementation, coverage and reimbursement)? Can certain
issues (e.g., the ethical and social ones) be better addressed by one
body versus another? A possible limitation of the literature review
is that overall the authors do not generally make a clear
distinction between the regulatory processes (those of the
FDA, EMA, and Health Canada that aim to allow the
marketing of AIHTs) and the HTA (which focus on assessing
implementation, optimal use, and whether or not to recommend
reimbursement by third-party payers), so it was not possible to
specify the unique considerations that arise specifically for either
or both. One thing is for certain, the exceptional challenges of
AIHT further raise the importance, for regulators and health
technology assessors, to consider the impacts of AI uses in
healthcare in a holistic way. This points to pivoting current
rather linear regulatory and HTA process towards a “lifecycle”
approach, which would allow for a better consideration of the five
exceptional dimensions of AIHT. This may sound demanding,
but AIHTs already represent additional evaluative burdens,
especially when it comes to long-term real-world usages (e.g.,
when AIHT are used on new populations or for new purposes
that differ from the data on which it was trained, or simply behave
differently fromwhat was expected at the time of the regulatory or
HTA assessment) and the difficulties of withdrawing AIHT from
the market. This calls for more cooperation between regulators
and HTA agencies, but also hint towards a global health
technology governance reform to allow increased scrutiny
capability, and also to help AIHT regulatory and HTA
assessment adjust overtime (i.e., by using a lifecycle approach)
based on the evolving (clinical, economic, social, ethical)
evidence.
In any case, there is a strong argument for taking into
consideration the exceptional aspects of AIHTs, especially as
their impacts on the healthcare systemwill be far greater than that
of drugs and medical devices (Vayena et al., 2018; Babic et al.,
2019). As AI applications begin to be much more readily
introduced into the health care sector, there is a window of
opportunity for HTA agencies and scholars to consider the broad
spectrum of impacts that AIHTs may generate (Bostrom and
Yudkowsky 2011; Helbing 2015; Burton et al., 2017; Herschel and
Miori 2017; Knoppers and Mark Thorogood 2017). AI
implementation by governments and health organizations
carries risks of generating new and amplifying existing,
challenges due to a shift from the current mostly human-
driven systems to new algorithm-driven systems (Vayena
et al., 2018; Zafar and Villeneuve 2018; Reddy et al., 2020).
Hence the need to address the distinct (without the need for
them to be exceptional) characteristics of AIHTs to inform HTA
developments in a way to ensure that only clinically,
economically, socially acceptable AIHTs are deployed in the
health care system.
CONCLUSION
Therefore, is it possible to assert that there is such thing as an AI
exceptionalism in HTA? It may be too early to be decisive on
this issue, although the literature reviewed seems to point in
this direction. Our review of the literature has allowed to
identify five dimensions through which AIHTs are
exceptional, from an HTA standpoint: nature, scope,
increased expectations, new ethical challenges and new
evaluative constrains. Most importantly, what underlies the
promises of AI, the hype, and the exceptionalism is that we are
mostly in an era of speculation; while some applications have
begun to work their way into the healthcare system, the much-
anticipated revolution is still a ways off. It is the test of time that
will determine the veracity and breadth of the exceptionalist
perspective. But whether or not exceptionalism proves to be
valid, HTA must certainly adapt to the massive arrival of AI in
health. This must be done by considering and responding to the
five dimensions of exceptionalism and their many implications
that can undermine the appropriateness, efficiency, and
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relevancy of current and future HTA infrastructure and
processes. Our results should help inform where HTA
stakeholders need to pay special attention and adapt their
policy architecture and processes so that they become agile
to adopt a regulatory posture capable of appreciating the
distinct characteristics and impacts that AIHTs pose in the
health sector.
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